EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety of Dupilumab in Treating Intrinsic and Extrinsic Atopic Dermatitis in Older Patients With and Without Atopic Comorbidities: A Retrospective Study

Kexin Zhao iD, Ge Yang, Xiyuan Zhou, Jianing Yang, Juhua Zhao, Jing Xiang, Xuejun Chen, LiXia Zhang iD

Dermatitis® · 2025

DOI: 10.1089/derm.2024.0402 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatitis®, 2025. Verfasst von Kexin Zhao und 7 weiteren Autor:innen. Beteiligte Einrichtung: From the Institute of Dermatology and Venereology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electr…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite the widespread use of dupilumab in atopic dermatitis (AD) treatment, evidence supporting its use in older patients with intrinsic AD (IAD) versus those with extrinsic AD (EAD) and in those with and without atopic comorbidities remains limited.

Objective

We aimed to assess the clinical efficacy and safety of dupilumab treatment in elderly patients with IAD versus EAD and in those with and without atopic comorbidities.

Methods

We enrolled 113 older patients with severe AD who received dupilumab for 48 weeks. The inclusion criteria were age ≥60 years and Scoring Atopic Dermatitis ≥25. Patients were classified as IAD or EAD and based on the presence of atopic comorbidities. The primary outcome was a reduction in the Eczema Area and Severity Index, Numeric Rating Scale, Dermatology Life Quality Index, and Atopic Dermatitis Control Test. Secondary measures were the types and rates of adverse events.

Results

Dupilumab treatment resulted in a substantial improvement in AD symptoms, with no significant difference between patients with IAD and EAD or those with and without atopic comorbidities.

Conclusions

Dupilumab showed good efficacy and safety in improving AD symptoms in older patients, irrespective of IAD or EAD subtypes and the presence of atopic comorbidities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedDermatologic AgentsHumansMaleFemaleAgedRetrospective StudiesMiddle AgedComorbidityTreatment OutcomeSeverity of Illness IndexAged, 80 and overQuality of Life

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedDermatologic Agents

Autor:innen und Institutionen

  • From the Institute of Dermatology and Venereology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
  • Department of Dermatology, Nanchong Central Hospital, Nanchong, China.

ORCID-Profile: Kexin Zhao, LiXia Zhang

Zitieren

APA

Zhao, K., Yang, G., Zhou, X., Yang, J., Zhao, J., Xiang, J., Chen, X., & Zhang, L. (2025). Efficacy and Safety of Dupilumab in Treating Intrinsic and Extrinsic Atopic Dermatitis in Older Patients With and Without Atopic Comorbidities: A Retrospective Study. Dermatitis®. https://doi.org/10.1089/derm.2024.0402

Vancouver

Zhao K, Yang G, Zhou X, Yang J, Zhao J, Xiang J, et al. Efficacy and Safety of Dupilumab in Treating Intrinsic and Extrinsic Atopic Dermatitis in Older Patients With and Without Atopic Comorbidities: A Retrospective Study. Dermatitis®. 2025. doi:10.1089/derm.2024.0402

BibTeX
@article{Zhao2025,
  author = {Zhao, Kexin and Yang, Ge and Zhou, Xiyuan and Yang, Jianing and Zhao, Juhua and Xiang, Jing and Chen, Xuejun and Zhang, LiXia},
  title = {Efficacy and Safety of Dupilumab in Treating Intrinsic and Extrinsic Atopic Dermatitis in Older Patients With and Without Atopic Comorbidities: A Retrospective Study},
  journal = {Dermatitis®},
  year = {2025},
  doi = {10.1089/derm.2024.0402}
}
Kostenlos starten →